|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||264.00 - 280.00|
|52 Week Range||183.00 - 444.00|
|PE Ratio (TTM)||39.17|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Q2 2017 Bavarian Nordic A/S Earnings Call
Danish biotech company Bavarian Nordic expects to get its first milestone payment under a deal with Janssen Pharmaceuticals in 2019, if clinical trials for vaccines targeting hepatitis B and HIV-1 get underway next year, a company executive said. Bavarian Nordic last month signed a deal with Janssen, a unit of Johnson & Johnson, with a potential value of up to $879 million including upfront, equity investment and milestone payments.
Danish biotech company Bavarian Nordic has expanded its collaboration with Janssen Pharmaceuticals, a unit of Johnson & Johnson, to also grant the U.S. drugmaker the exclusive rights to its MVA-BN technology for vaccine programmes targeting hepatitis B and HIV-1.